Search
2026
2025
2024
2023
-
Jul 20, 2026
YolTech Therapeutics Appoints Jessie Yeung as Chief Financial OfficerRead More
-
May 29, 2026
YolTech Therapeutics Raises $70 Million in Series C FinancingRead More
-
May 14, 2026
YolTech Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation to YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Read More
-
Mar 13, 2026
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)Read More
-
Mar 04, 2026
YolTech Therapeutics Reports 24-Week Clinical Data for YOLT-101 in Nature MedicineRead More
